Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Regen BioPharma, Inc. Reports Success Of Its NR2F6 Small Molecule Screening Program For Treating Autoimmune Diseases

|About: Regen BioPharma, Inc. (RGBP)
Summary

Shows Potential to Treat Lupus.

Immunology/Immunotherapy.

Cancers & Auto Immune Diseases.

Regen BioPharma, Inc.

Regen BioPharma Inc. (RGBP) and (RGBPP), has identified a series of small molecule drugs that inhibit NR2F6. Regen's screening process demonstrated that its recently identified novel chemical compounds appear to inhibit NR2F6 and show potential for treating autoimmune diseases such as Lupus.

Read More

https://finance.yahoo.com/news/regen-biopharma-inc-reports-success-130000088.html

Focused on Rapidly Advancing Novel Technologies/Oral Therapies

Lead Drug Candidate RG-NAE005 No Toxicity-Moving on to Efficacy Phase

Pre-Clincal - Phase I & II Patients Trials-Using Patient Immune Systems

Should Suppress Immune System Diseases Immunology-Immunotherapy

Additionally

Agremment with Eli Lily (LLY) - Providing Compounds For

Cancers

Breast, Bladder, Lung, Liver, Leukemia

Auto Immune Diseases & Disorders

Rheumatoid Arthritis, IBS, Psoriasis

It is our opinion that (OTCPK:RGBP) is a Long Play that poses an opportunity for Short Term Gains/Profit as well. This historically has been evident.

If you require more information- please feel free to contact me.

Robert E. Kreh – Principal

Small Cap Solutions, LLC

robkreh@smallcapsolutions.com

(443) 567-2609

https://www.smallcapsolutions.com

(OTCQB:RGBP) Disclaimer: You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at . Small Cap Solutions, LLC has received payment from a Third Party for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclaimer: All Micro/Small Cap Company(ies) profile() are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at and/or Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.

Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker( S )/Broker Dealer with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.